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Abstract. Alzheimer and Parkinson diseases are age-
related neurodegenerative disorders in which formation
of amyloid aggregates by amyloid-beta (Abeta) and
α-synuclein (αS) proteins, respectively, are recognised
critical events that occur early in the disease process.
These aggregates cause disruption of mitochondrial
function in neurons, initiating a pathophysiological
cascade leading to bio-energetic collapse and ultimately
neuronal cell death. The detailed mechanisms are,
however, largely unknown. In vitro studies in our
laboratory aimed to, (i) investigate destabilisation
of mitochondrial phospholipid membranes by these
amyloid aggregates and, (ii) explore the protective
effect of select polyphenolic compounds on mitochon-
dria. Exposure of mitochondria, isolated from human
neuroblastoma SH-SY5Y cells, to amyloid aggregates
induced a strong and dose-dependent release of cy-
tochrome c, reflecting damage to the outer and/or inner
mitochondrial membranes. Importantly, targeting of
aggregates to mitochondria was shown to be dependent
upon cardiolipin, a mitochondria-specific phospholipid
known to play a critical role in launching apoptosis.
Moreover, the ability of amyloid aggregates to damage
mitochondrial membranes was confirmed using a
liposome permeabilisation assay. Finally, we found
that the polyphenol compounds morin, rosmarinic
acid, epigallocatechingallate and black tea extract were
potent mito-protectants, and may thus delay the onset
of neurodegenerative diseases.
Keywords Alzheimer’s disease – Parkinson’s disease –
amyloid-beta – α-synuclein – mitochondrial membrane
– permeabilisation – cardiolipin – polyphenols.
1 Introduction
Alzheimer’s disease (AD) and Parkinson’s disease
(PD) are incurable neurodegenerative disorders that are
generally prevalent in the elderly population. Epidemi-
ological studies in humans, as well as molecular stud-
ies in toxin-induced and genetic animal models of AD
and PD show that mitochondrial dysfunction is a de-
fect occurring early in the pathogenesis of both dis-
eases (Bu¨eler, 2009). Mounting evidence indicates that
mitochondrial abnormalities triggered by small, soluble
prefibrillar aggregates (termed oligomers) are early oc-
currences, preceding neurological pathology and clinical
symptoms characteristic of both AD and PD. Perfora-
tion of mitochondrial membranes leads to the release of
pro-apoptotic proteins such as cytochrome c (Cyto c)
into the cellular cytosol, triggering neuronal apoptosis
(Lin et al., 2009). In addition, epidemiological studies
have associated nutrition components, such as polyphe-
nols, to lower incidence of such neurodegenerative dis-
eases, though the molecular basis for their protective
effect is not known (de Lau and Breteler, 2006).
The aim of this paper is to describe in vitro studies
that have been carried out in our laboratory which de-
termine: (i) the effects of specific amyloid-beta (Abeta)
and α-synuclein (αS) oligomeric aggregates on synthetic
and cellular mitochondrial membranes, and (ii) identify
mitochondrial-protective polyphenolic compounds. The
first part of the report provides a background on the
pathophysiological effects of such oligomeric proteins on
mitochondria, followed by a brief description of the ac-
complished experiments.
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2 An overview of mitochondrial
dysfunction in AD and PD
Mitochondria are organelles enclosed by a double
membrane and are essential for cell viability. They are
partitioned into four main compartments: the outer mi-
tochondrial membrane (OMM), inter-membrane space
(IMS), inner mitochondrial membrane (IMM) and ma-
trix (Bogaerts et al., 2008). These organelles possess
important functions within the cell, such as generation
of adenosine triphosphate (ATP) during oxidative phos-
phorylation (Hausmann et al., 2008), homeostatic con-
trol of cytosolic calcium and iron concentration (Feiss-
ner et al., 2009), iron-sulfur (Fe/S) cluster and heme
biogenesis (Lill and Mu¨hlenhoff, 2005; Rouault and
Tong, 2005) and also contribute to programmed cell
death (Garrido and Kroemer, 2004). The critical role of
a mitochondrial-specific phospholipid, cardiolipin (CL)
in the apoptotic process has been extensively reported
(Bradley et al., 2011; Korytowski et al., 2011). Car-
diolipin is essentially an IMM phospholipid, since it is
only present in minute quantities in the OMM, possibly
through inner-to-outer mitochondrial membrane contact
sites (de Kroon et al., 1997; Gonzalvez and Gottlieb,
2007). This phospholipid is critical for the optimal func-
tion of numerous enzymes that are involved in mitochon-
drial energy metabolism. Moreover, the formation of
OMM openings required for the release of pro-apoptotic
proteins such as Cyto c into the cytosol, was dependent
on the presence of CL (Kuwana et al., 2002). While it
is clear that some type of opening develops in the OMM
during death signalling to allow exit of apoptogenic pro-
teins from the IMS, the molecular nature and regulation
of this pore remain unclear (Smith et al., 2005; Cheng
et al., 2010).
2.1 Parkinson’s disease
PD is distinguished from other forms of parkinsonism
by the presence of Lewy bodies (LBs) and Lewy neu-
rites (LNs), which are juxtanuclear and neuritic ubiq-
uitinated protein aggregates composed predominantly
of the synaptic protein αS (Shults, 2006). Cumula-
tive evidence now suggests that the abnormal aggre-
gation of this neuronal protein is critically involved in
the pathogenesis of PD. The presence of mitochondrial
dysfunction is noteworthy given the evidence already
implicating mitochondrial toxins in the pathogenesis of
PD (Camilleri and Vassallo, 2014). Sporadic forms
of PD are attributed to environmental contaminants;
substances like rotenone and 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) inhibit complex I and also
promote Cyto c release from the IMS (Perier et al., 2005;
Banerjee et al., 2010). αS has been shown to interfere at
various intracellular sites, including vesicle membranes
(Iwai et al., 1995), mitochondria (Hsu et al., 2000), the
cell death pathway (da Costa et al., 2006), the protea-
some (Tanaka et al., 2001), and the Golgi apparatus
(Gosavi et al., 2002). Although subcellular αS is largely
cytosolic, a fraction of it was shown to be present in, or
associated with, mitochondria (Nakamura et al., 2008).
Devi and colleagues demonstrated import of αS into mi-
tochondria and there it is shown to be predominantly
associated with the IMM. This membrane association
is due to the presence of a mitochondrial targeting sig-
nal and is dependent upon mitochondrial membrane po-
tential, ATP levels and the oxidation of mitochondrial
proteins (Devi et al., 2008; Parihar et al., 2008). Of in-
terest is the fact that subcellular distribution of αS was
found to be uneven between different brain regions, with
higher levels of mitochondrial αS in the hippocampus,
striatum and substantia nigra (Zhang et al., 2008).
A number of experimental studies suggest that αS
may be closely linked to mitochondrial dysfunction and
oxidative stress. An increase in the amount of αS
binding with mitochondria was shown to be due to
over-expression of αS in cell cultures (Shavali et al.,
2008; Cole et al., 2008). Studies in yeast cells have
demonstrated that abrogation of mitochondrial DNA
prevented αS-induced reactive oxygen species (ROS) for-
mation and apoptosis, implying that mitochondria are
necessary in mediating the toxicity of αS (Bu¨ttner et
al., 2008). Moreover, over-expression of A53T mutant
αS was shown to induce Cyto c release and activation
of downstream caspases in rat PC12 cells, resulting in
apoptosis (Smith et al., 2005). Furthermore, associa-
tion of αS to mitochondria in cells was also related to
oxidation of mitochondrial proteins and elevated levels
of calcium and nitric oxide (Parihar et al., 2008). The
amount of αS associated with mitochondria seems to
correlate with mitochondrial dysfunction.
Mitochondrial defects were also observed in numer-
ous transgenic mouse models over-expressing wild-type
(WT) or mutant αS. Some examples comprise selective
oxidation of metabolic proteins related to mitochondria
(Poon et al., 2005), evidence of mitochondrial pathol-
ogy after treatment with MPTP (Song et al., 2004),
deterioration of mitochondria containing αS including
decreased complex IV activity and mitochondrial DNA
damage (Martin et al., 2006). Worthy of note is the fact
that some of the reported mitochondrial alterations due
to expression of WT or A53T αS in mice were observed
early in the disease process (Abou-Sleiman et al., 2006).
These animal models suggest that αS may have a phys-
iological role in mitochondria, and that the mitochon-
drial defects may be the result of a toxic gain-of-function
due to over-expressed or mutated αS present in mito-
chondria (Bu¨eler, 2009). In contrast, mice lacking αS
expression also show mitochondrial dysfunction that is
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manifested by altered plasma membrane lipid composi-
tion and reduced performance of the electron transport
mitochondrial complex I and III activity (Ellis et al.,
2005). As both the lack and overexpression of αS have
adverse effects on neuronal mitochondria, the physiolog-
ical equilibrium seems to be of pivotal importance.
2.2 Alzheimer’s disease
AD is characterised by neuronal degeneration in the
presence of extracellular plaque deposits of Abeta pep-
tides in specific brain regions and intraneuronal, neu-
rofibrillary tangles (NFTs) related to the hyperphospho-
rylation of the Tau protein in affected neurons (Murphy
and LeVine, 2010). Mitochondria may be a common
early target of both Abeta and Tau in AD. Gotz and co-
workers reported an independent and synergistic action
of both peptides on mitochondria leading to bioenergetic
defects and increased oxidative stress in a triple trans-
genic mouse model exhibiting both pathological features
of the disease (Eckert et al., 2010). The progressive mi-
tochondrial accumulation of Abeta has been observed
in the AD brain. Image analysis revealed accumulation
of Abeta in 40 % and 70 % of mitochondria in the tem-
poral lobe and hippocampus respectively, compared to
5 % and 14 % in non-AD brains (Chen and Yan, 2010).
Abnormal mitochondrial gene expression, mitochondrial
accumulation of Abeta and Abeta–dependent mitochon-
drial dysfunction were detected in AD transgenic mice
from as early as 2-4 months of age, before the occurrence
of cognitive difficulties (Reddy et al., 2004; Hauptmann
et al., 2009; Du et al., 2010). In addition, mitochondrial
dysfunction was observed to occur regardless of the ge-
netic mutation involved, and lead to specific metabolic
changes which could be used as biomarkers for the early
diagnosis of AD (Trushina et al., 2012). These findings
highlight the early and important involvement of mito-
chondria in the disease. Abeta-induced mito-toxicity is
associated with decreased ATP production (Blass et al.,
2002), increased ROS levels and oxidative stress (Ro-
drigues et al., 2001; Felice et al., 2007), disturbances of
Ca2+ homeostasis (Sanz-Blasco et al., 2008), and desta-
bilisation of mitochondrial membranes, amongst others.
Nevertheless, the exact pathway and sequence through
which these events occur remains unclear (Canevari et
al., 2004).
To summarise, evidence suggests that mitochondrial
dysfunction and intrinsic mitochondrial-mediated apop-
tosis play a key role in molecular cell death pathways of
AD and PD (Northington et al., 2005; Martin, 2010).
Several mechanisms of Abeta and αS-induced neurotox-
icity have been proposed. Loss of normal cellular home-
ostasis and damage to cellular organelles such as mi-
tochondria may indicate a unifying toxic cause: mem-
brane permeation. Research reports support the hy-
pothesis that Abeta and αS oligomers share a com-
mon mechanism of toxicity. Indeed, a common con-
formation unique to soluble oligomers has been iden-
tified (Glabe and Kayed, 2006), which specifically lead
to permeabilisation of lipid bilayers regardless of pro-
tein sequence (Kayed et al., 2004). The importance of
oligomer-induced mitochondrial impairments lies with
their early and direct involvement in the pathogenesis
of PD and AD (Cha et al., 2012; Trushina et al., 2012).
Thus, drugs or natural compounds with the potential to
adjust mitochondrial dynamics, function and biogenesis
may help in attenuating the onset of both AD and PD.
3 Polyphenols as mito-protec-
tants in vitro
Substantial evidence from the reviewed literature sug-
gests that mitochondria are one of the main intracellular
compartments linking the processes between the aggre-
gation of Abeta and αS and final dopaminergic neuronal
degeneration. Several natural polyphenolic compounds
have been demonstrated to specifically and efficiently
hinder the aggregation process of αS (Caruana et al.,
2011). In our lab, we have also demonstrated the in-
hibitory effect of selected polyphenols and extracts on
membrane damage, induced by αS and Abeta oligomers
(Gauci et al., 2011; Caruana et al., 2012). On the basis
of these results, we have extended our studies to inves-
tigate the destabilisation of synthetic and isolated mi-
tochondrial phospholipid membranes by amyloid aggre-
gates. The ultimate goal here was to establish whether
mitochondrial membranes could be protected against
amyloid-induced dysfunction by these promising groups
of bioactive small-molecule compounds and extracts.
3.1 Amyloid aggregate-induced mito-
toxicity
The first part of the study investigated the direct tox-
icity of Abeta and WT/mutant αS (A53T, A30P) ag-
gregates on synthetic mitochondrial membranes. Lipo-
some systems mimicking mitochondrial membranes have
been used successfully in ascertaining the membrane
permeabilising abilities of amyloid proteins (Epand et
al., 2002; Kuwana et al., 2002; van Meer et al., 2008;
Williams et al., 2010). The four types of synthetic lipid
vesicle membranes used here mimic mitochondrial outer
and inner membrane composition, as well as that of the
neuronal plasma membrane for comparison (Table 1).
Assessment of vesicle permeabilisation by aggre-
gated Abeta and WT/mutant αS was performed using
fluorescence-based methods on such mitochondrial-like
model systems. Essentially, the amyloid proteins were
able to directly perforate the artificial mitochondrial
membranes. We further noted that this effect was highly
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Table 1: Phospholipid composition of IM-, OM- and L-type liposome membranes. OM-type liposomes - characteristic of
mitochondrial membranes; IM-type liposomes - characteristicof inner mitochondrial membranes; L-type liposomes - characteristic
of mitochondrial membranes but lacking cardiolipin.
Phospholipid % composition
IM-type OM-type L-type
L-α-phosphatidylcholine (PC) 38 46.5 50.1
L-α-phosphatidylethanolamine (PE) 24 28.4 30.6
L-α-phosphatidylinositol (PI) 16 8.9 9.6
L-α-phosphatidylserine (PS) 4 8.9 9.6
Cardiolipin (CL) 18 7.3 -
dependent upon the presence of specific low-molecular-
weight oligomeric species. In a further series of lipo-
somal studies we discovered that mitochondria-specific
lipid CL particularly enhanced permeabilisation by αS
and Abeta (Chicco and Sparagna, 2007; Cole et al.,
2008; Camilleri et al., 2013). Therefore it can be inferred
from our experiments that IM-type membranes (rich in
CL) are especially susceptible to Abeta and αS toxic-
ity. Indeed, IM-membranes contain twice as much CL as
OM-liposomes, whilst L-type liposomes (which lack CL)
were the least damaged by the protein aggregates. Ac-
cordingly, it was suggested that mitochondria-localised
αS is predominantly associated with the inner membrane
in dopaminergic neuronal cell cultures and PD brains
(Devi and Anandatheerthavarada, 2010). This supports
recent data stating that oligomeric αS target disruption
of lipid vesicles having negatively charged membranes
and that CL is essential for the interaction between WT
and A30P αS with large unilamellar vesicles whose com-
position is similar to that of the IMM (van Rooijen et
al., 2009; Zigoneanu et al., 2012). In addition, it was
reported that CL was the phospholipid found to most
strongly stimulate Abeta aggregation (CL > PI > PS
> PC = PE) (Chauhan et al., 2000) and that affinity
of αS to CL possibly drives mitochondrial fission by αS
oligomers, but not monomers (Nakamura et al., 2011).
It is thus highly plausible that exclusive properties of
the mitochondria-specific CL (see review by Szeto, 2014)
provide a platform for rapid and enhanced membrane
destabilisation by amyloid aggregates. These results in-
dicate a pivotal pathway of neuronal apoptosis induction
and intriguingly suggest a common toxic mechanism for
the three aggregation-prone peptides.
An important endeavour of the study was to extrap-
olate the findings from the liposome permeabilisation
assays to the membranes of respiring mitochondria iso-
lated from a neuronal cell line. Interaction of aggre-
gated Abeta and αS with the mitochondrial membrane
lead to its disruption and release of the respiratory pro-
tein Cyto c, hence initiating mitochondrial-driven cell
death pathways in neurons. For this purpose, a proto-
col was first established for isolation of fresh intact mi-
tochondria from the SH-SY5Y human neuronal cell line.
Subsequently, the isolated mitochondria were exposed to
the proteins in question in order to determine whether
this would damage the outer and/or inner mitochon-
drial membranes, specifically by inducing Cyto c release
(CCR) from IMS. This was determined by means of a
quantitative enzyme-linked immunosorbent assay. We
reported that aggregated, but not monomeric, Abeta
and WT/mutant αS disrupted the mitochondrial mem-
brane leading to CCR. Taken together, the various in
vitro neuronal models may indicate that amyloid mis-
folding is naturally paralleled to mitochondrial apopto-
sis and may contribute to neurodegeneration.
3.2 Polyphenols inhibit cytochrome c
release from mitochondria
Polyphenolic compounds are naturally-present con-
stituents of a wide variety of fruits, vegetables, food
products and beverages derived from plants such as
olive oil, tea, and red wine (Stevenson and Hurst, 2007).
They are characterised by a polyphenol structure (Fig-
ure 1), which generally consists of two aromatic rings
(2-phenyl-1,4-benzopyrone), each containing at least one
hydroxyl group, which are connected via a three-carbon
bridge and become part of a six-member heterocyclic
ring (Beecher, 2003; Porat et al., 2006; D’Archivio et al.,
2007). In the current literature, very few studies have
to date examined the protective effect of polyphenols
on amyloid-induced mitochondrial dysfunction. For in-
stance, the flavone baicalein reduced the MMP-lowering
effect of (E34K) mutant αS in whole cells (Jiang et al.,
2010) and grape fruit extract protected mitochondria in
a Drosophila model of PD (Long et al., 2009). Thus,
it was relevant to investigate whether small-molecule
polyphenols are able to suppress CCR from the IMS
and therefore act as mito-protectants.
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Figure 1: General structure and numbering pattern for
common food polyphenols (adapted from (Beecher, 2003)).
This figure shows the general structure and numbering
pattern for common polyphenolic compounds. For most
food flavonoids, R4′=H, R5=OH and R6=H. Individual
flavonoids within each subclass are characterised by unique
functional groups at R3, R3′, and R5′.
The relative efficacy of small-molecule compounds on
preventing CCR from mitochondria was also determined
by means of a quantitative enzyme-linked immunosor-
bent assay. The results demonstrated that the mito-
chondrial membrane can indeed be protected against
αS/Abeta-induced disruption by a group of polyphe-
nolic compounds, specifically by suppressing CCR.
Seven polyphenolic compounds (apigenin, baicalein,
epigallocatechin-gallate [ECGC], morin, nordihydrogua-
iaretic acid [NDGA] and rosmarinic acid [RA]) and
black tea extract [BTE] were able to significantly limit
CCR induced by aggregated WT/mutant αS and Abeta
(Camilleri et al., 2013). It was encouraging to note that
these compounds also featured as the top six compounds
in the liposome permeabilisation assay. Hence, such
experiments show that polyphenols constitute a major
class of compounds that can indeed protect mitochon-
drial damage from αS and Abeta oligomeric assemblies
at the membrane. Data emerging from our laboratory
provides support to studies exploring the therapeutic
potential of inhibitors of apoptosis proteins (IAPs) by
raising the threshold of CCR required for commitment
to apoptosis (Clayton et al., 2005).
4 Conclusion
It is increasingly evident that misfolded and aggre-
gated disease proteins are not simply neuropathologic
markers of neurodegenerative disorders but, instead, al-
most certainly contribute to disease pathogenesis. Our
research was driven by the fact that formation of amy-
loid aggregates and mitochondria-induced apoptosis of
neurons are critical events in the pathophysiology of
these neurodegenerative diseases. Most importantly,
mitochondrial dysfunction precedes neurological pathol-
ogy and clinical symptoms characteristic of AD and PD.
Liposomal studies and CCR assays on isolated neu-
ronal mitochondria in our laboratory clearly showed
that specific proteins involved in AD and PD are able
to permeate mitochondrial membranes and this abil-
ity is markedly dependent on aggregation conditions.
Release of Cyto c suggests major disruption of mito-
chondrial membranes and is probably enough to induce
neuronal apoptosis. An important finding underscored
by liposomal studies is the prominent contribution of
CL to both αS and Abeta-induced mitochondrial per-
meabilisation, accounting for the selective disruption of
mitochondrial-like membranes as opposed to cellular-
like membranes, and thus suggesting a common underly-
ing mechanism of toxicity. Screening of a select group of
small drug molecules and extract yielded potential mito-
protective agents with shared structural characteristics
against toxicity induced by Abeta and αS aggregates.
The in vitro assays performed in our studies are thus
valid tools for the identification of potential therapeutic
agents for subsequent in vitro analysis, hopefully arrest-
ing AD/PD at an early stage. In such debilitating mal-
adies where no cure is available, increasing prevalence
and high economic burden urgently necessitate disease-
modifying treatment.
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